{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:11:57Z","timestamp":1791357117144,"version":"4.3.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,10,3]],"date-time":"2014-10-03T00:00:00Z","timestamp":1412294400000},"content-version":"vor","delay-in-days":2,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/3.0\/"}],"funder":[{"DOI":"10.13039\/100015756","name":"Cilag","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015756","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.clinthera.2014.08.014","type":"journal-article","created":{"date-parts":[[2014,10,22]],"date-time":"2014-10-22T23:01:07Z","timestamp":1414018867000},"page":"1372-1388.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["A Prospective Flexible-Dose Study of Paliperidone Palmitate in Nonacute But Symptomatic Patients With Schizophrenia Previously Unsuccessfully Treated With Oral Antipsychotic Agents"],"prefix":"10.1016","volume":"36","clinical-trial-number":[{"clinical-trial-number":"nct01281527","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Andreas","family":"Schreiner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Bergmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Cherubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Keim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmars","family":"Rancans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasin","family":"Bez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Parellada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Carpiniello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Vidailhet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Hargarter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2014.08.014_bib1","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.2147\/NDT.S37485","article-title":"Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments","volume":"9","author":"Chien","year":"2013","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.clinthera.2014.08.014_bib2","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.4088\/JCP.12117tx1c","article-title":"Improving patient outcomes in schizophrenia: achieving remission, preventing relapse, and measuring success","volume":"74","author":"Kane","year":"2013","journal-title":"J Clin Psychiatry"},{"issue":"suppl 5","key":"10.1016\/j.clinthera.2014.08.014_bib3","first-page":"3","article-title":"Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia","volume":"67","author":"Leucht","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2014.08.014_bib4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.4088\/JCP.09m05459yel","article-title":"Relapse prevention in first-episode schizophrenia\u2014maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia","volume":"72","author":"Gaebel","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2014.08.014_bib5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0920-9964(01)00182-7","article-title":"First vs multiple episode schizophrenia: two-year outcome of intermittent and maintenance medication strategies","volume":"53","author":"Gaebel","year":"2002","journal-title":"Schizophr Res"},{"key":"10.1016\/j.clinthera.2014.08.014_bib6","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1176\/appi.ajp.2011.10081224","article-title":"A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia","volume":"168","author":"Tiihonen","year":"2011","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2014.08.014_bib7","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1176\/ps.2007.58.6.844","article-title":"Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia","volume":"58","author":"Byerly","year":"2007","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.clinthera.2014.08.014_bib8","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1742-1241.2012.02918.x","article-title":"Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians\u2019 perceptions of adherence vs. pharmacy claims","volume":"66","author":"Stephenson","year":"2012","journal-title":"Int J Clin Pract"},{"issue":"suppl 1","key":"10.1016\/j.clinthera.2014.08.014_bib9","first-page":"58","article-title":"Understanding depot antipsychotics: an illustrated guide to kinetics","volume":"18","author":"Meyer","year":"2013","journal-title":"CNS Spectr"},{"key":"10.1016\/j.clinthera.2014.08.014_bib10","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/JCP.0b013e318167269d","article-title":"Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study","volume":"28","author":"Emsley","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2014.08.014_bib11","doi-asserted-by":"crossref","first-page":"e541","DOI":"10.4088\/JCP.11m07138","article-title":"Symptom recurrence following intermittent treatment in first-episode schizophrenia successfully treated for 2 years: a 3-year open-label clinical study","volume":"73","author":"Emsley","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2014.08.014_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/oxfordjournals.schbul.a033315","article-title":"Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort","volume":"24","author":"Wiersma","year":"1998","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.clinthera.2014.08.014_bib13","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1471-244X-8-32","article-title":"Non-adherence to antipsychotic medication, relapse and rehospitalisation in recent-onset schizophrenia","volume":"8","author":"Morken","year":"2008","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.clinthera.2014.08.014_bib14","first-page":"147","article-title":"Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: a review","volume":"11","author":"Masand","year":"2009","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"suppl 4","key":"10.1016\/j.clinthera.2014.08.014_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4088\/JCP.7090su1cj","article-title":"The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness","volume":"70","author":"Velligan","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2014.08.014_bib16","first-page":"5","article-title":"Maintenance treatment with antipsychotic drugs for schizophrenia","author":"Leucht","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2014.08.014_bib17","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1176\/appi.ajp.2013.12050674","article-title":"Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study","volume":"170","author":"Andreasen","year":"2013","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2014.08.014_bib18","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/sj.npp.1301347","article-title":"Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-up study","volume":"32","author":"van Haren","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.clinthera.2014.08.014_bib19","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2165\/00019053-200826020-00005","article-title":"The burden of schizophrenia on caregivers: a review","volume":"26","author":"Awad","year":"2008","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.clinthera.2014.08.014_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.4088\/JCP.v69n0107","article-title":"A longitudinal study of medication nonadherence and hospitalization risk in schizophrenia","volume":"69","author":"Law","year":"2008","journal-title":"J Clin Psychiatry"},{"issue":"10 suppl 17","key":"10.1016\/j.clinthera.2014.08.014_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1017\/S1092852900026304","article-title":"Treatment adherence and long-term outcomes","volume":"12","author":"Kane","year":"2007","journal-title":"CNS Spectr"},{"key":"10.1016\/j.clinthera.2014.08.014_bib22","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0140-6736(08)61817-6","article-title":"Global pattern of experienced and anticipated discrimination against people with schizophrenia: a cross-sectional survey","volume":"373","author":"Thornicroft","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2014.08.014_bib23","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1176\/appi.ajp.2013.13010060","article-title":"Life satisfaction among individuals with schizophrenia in the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) study","volume":"170","author":"Fervaha","year":"2013","journal-title":"Am J Psychiatry"},{"issue":"suppl 1","key":"10.1016\/j.clinthera.2014.08.014_bib24","first-page":"4","article-title":"Strategies for dosing and switching antipsychotics for optimal clinical management","volume":"69","author":"Buckley","year":"2008","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2014.08.014_bib25","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2014.08.014_bib26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s40261-012-0047-8","article-title":"Improving treatment adherence in your patients with schizophrenia: the STAY initiative","volume":"33","author":"Ca\u00f1as","year":"2013","journal-title":"Clin Drug Investig"},{"issue":"suppl 14","key":"10.1016\/j.clinthera.2014.08.014_bib27","first-page":"27","article-title":"Treatment strategies to prevent relapse and encourage remission","volume":"68","author":"Kane","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2014.08.014_bib28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2010.11.020","article-title":"Oral versus depot antipsychotic drugs for schizophrenia\u2014a critical systematic review and meta-analysis of randomised long-term trials","volume":"127","author":"Leucht","year":"2011","journal-title":"Schizophr Res"},{"key":"10.1016\/j.clinthera.2014.08.014_bib29","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/schbul\/sbs150","article-title":"Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials","volume":"40","author":"Kishimoto","year":"2014","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.clinthera.2014.08.014_bib30","doi-asserted-by":"crossref","first-page":"568","DOI":"10.4088\/JCP.12r08167","article-title":"Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs","volume":"74","author":"Kirson","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2014.08.014_bib31","doi-asserted-by":"crossref","first-page":"957","DOI":"10.4088\/JCP.13r08440","article-title":"Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies","volume":"74","author":"Kishimoto","year":"2013","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2014.08.014_bib32","doi-asserted-by":"crossref","first-page":"s20","DOI":"10.1192\/bjp.195.52.s20","article-title":"First-generation antipsychotic long-acting injections v. oral antipsychotics in schizophrenia: systematic review of randomised controlled trials and observational studies","volume":"195","author":"Haddad","year":"2009","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.clinthera.2014.08.014_bib33","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1001\/jama.2014.4310","article-title":"Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial","volume":"311","author":"McEvoy","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2014.08.014_bib34","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.pnpbp.2009.05.014","article-title":"Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia","volume":"33","author":"Hough","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.clinthera.2014.08.014_bib35","unstructured":"Xeplion SmPC. Janssen. December 2013."},{"key":"10.1016\/j.clinthera.2014.08.014_bib36","unstructured":"Invega Susstenna PI. Janssen. August 2012."},{"key":"10.1016\/j.clinthera.2014.08.014_bib37","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/YIC.0b013e32833948fa","article-title":"Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study","volume":"25","author":"Gopal","year":"2010","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2014.08.014_bib38","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/npp.2010.79","article-title":"A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia","volume":"35","author":"Nasrallah","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.clinthera.2014.08.014_bib39","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/JCP.0b013e3181dd3103","article-title":"A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia","volume":"30","author":"Pandina","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2014.08.014_bib40","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","article-title":"The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials","volume":"58","author":"Marder","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2014.08.014_bib41","first-page":"323","article-title":"Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning","volume":"101","author":"Morosini","year":"2000","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.clinthera.2014.08.014_bib42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0920-9964(00)00166-3","article-title":"Improvement of schizophrenic patients\u2019 subjective well-being under atypical antipsychotic drugs","volume":"50","author":"Naber","year":"2001","journal-title":"Schizophr Res"},{"key":"10.1016\/j.clinthera.2014.08.014_bib43","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.clinthera.2014.08.014_bib44","doi-asserted-by":"crossref","first-page":"s21","DOI":"10.1192\/bjp.177.39.s21","article-title":"Caregiving in schizophrenia: development, internal consistency and reliability of the Involvement Evaluation Questionnaire\u2013European Version. EPSILON Study 4. European Psychiatric Services: Inputs Linked to Outcome Domains and Needs","author":"van Wijngaarden","year":"2000","journal-title":"Br J Psychiatry Suppl"},{"key":"10.1016\/j.clinthera.2014.08.014_bib45","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1055\/s-2004-834786","article-title":"[The \u201cMini-ICF-Rating for Mental Disorders (Mini-ICF-P)\u201d. A short instrument for the assessment of disabilities in mental disorders]","volume":"44","author":"Linden","year":"2005","journal-title":"Rehabilitation (Stuttg)"},{"key":"10.1016\/j.clinthera.2014.08.014_bib46","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-0029-1220740","article-title":"[Analyzing the effectiveness of inpatient psychosomatic rehabilitation using the mini-ICF-APP]","volume":"48","author":"Baron","year":"2009","journal-title":"Rehabilitation (Stuttg)"},{"key":"10.1016\/j.clinthera.2014.08.014_bib47","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s00127-012-0604-8","article-title":"The reliability, validity, and applicability of an English language version of the Mini-ICF-APP","volume":"48","author":"Molodynski","year":"2013","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"10.1016\/j.clinthera.2014.08.014_bib48","first-page":"233","article-title":"Extrapyramidal rating scale","volume":"7","author":"Chouinard","year":"1980","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.clinthera.2014.08.014_bib49","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00004850-200505000-00001","article-title":"Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies","volume":"20","author":"M\u00f6ller","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2014.08.014_bib50","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.eurpsy.2008.12.002","article-title":"Long-term outcomes in patients with schizophrenia treated with risperidone long-acting injection or oral antipsychotics in Spain: results from the electronic Schizophrenia Treatment Adherence Registry (e-STAR)","volume":"24","author":"Olivares","year":"2009","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.clinthera.2014.08.014_bib51","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/11599080-000000000-00000","article-title":"Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable","volume":"32","author":"Rosa","year":"2012","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2014.08.014_bib52","first-page":"26","article-title":"A Post-hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia","volume":"8","author":"Gopal","year":"2011","journal-title":"Innov Clin Neurosci"},{"key":"10.1016\/j.clinthera.2014.08.014_bib53","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1744-859X-10-12","article-title":"Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial","volume":"10","author":"Alphs","year":"2011","journal-title":"Ann Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2014.08.014_bib54","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1524-4733.2008.00495.x","article-title":"Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study","volume":"12","author":"Alonso","year":"2009","journal-title":"Value Health"},{"key":"10.1016\/j.clinthera.2014.08.014_bib55","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2147\/PPA.S15337","article-title":"Opinions of French patients with schizophrenia regarding injectable medication","volume":"5","author":"Caroli","year":"2011","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.clinthera.2014.08.014_bib56","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/YIC.0b013e3280c28424","article-title":"The attitude of patients towards antipsychotic depot treatment","volume":"22","author":"Heres","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2014.08.014_bib57","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1177\/0269881108092124","article-title":"Depot and oral antipsychotics: patient preferences and attitudes are not the same thing","volume":"23","author":"Patel","year":"2009","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.clinthera.2014.08.014_bib58","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.schres.2010.09.003","article-title":"Symptomatic remission and associated factors in a catchment area based population of older patients with schizophrenia","volume":"126","author":"Meesters","year":"2011","journal-title":"Schizophr Res"},{"key":"10.1016\/j.clinthera.2014.08.014_bib59","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.schres.2009.09.019","article-title":"Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST)","volume":"115","author":"Boter","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.clinthera.2014.08.014_bib60","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1093\/schbul\/sbs130","article-title":"A systematic review and meta-analysis of recovery in schizophrenia","volume":"39","author":"Jaaskel\u00e4inen","year":"2013","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.clinthera.2014.08.014_bib61","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1055\/s-2008-1076729","article-title":"Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia","volume":"41","author":"de Haan","year":"2008","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.clinthera.2014.08.014_bib62","doi-asserted-by":"crossref","first-page":"729","DOI":"10.3109\/15622971003690289","article-title":"Quality of life and subjective well-being in schizophrenia and schizophrenia spectrum disorders: valid predictors of symptomatic response and remission?","volume":"11","author":"Schennach-Wolff","year":"2010","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.clinthera.2014.08.014_bib63","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1176\/appi.ajp.159.1.103","article-title":"Antipsychotic medication adherence: is there a difference between typical and atypical agents?","volume":"159","author":"Dolder","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2014.08.014_bib64","doi-asserted-by":"crossref","first-page":"131","DOI":"10.31887\/DCNS.2006.8.1\/wmillas","article-title":"The impact of subjective well-being under neuroleptic treatment on compliance and remission","volume":"8","author":"de Millas","year":"2006","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.clinthera.2014.08.014_bib65","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.schres.2005.12.857","article-title":"A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA)","volume":"84","author":"Tandon","year":"2006","journal-title":"Schizophr Res"},{"key":"10.1016\/j.clinthera.2014.08.014_bib66","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1037\/a0031256","article-title":"Accuracy of self-report, biological tests, collateral reports and clinician ratings in identifying substance usedisorders among adults with schizophrenia","volume":"27","author":"Desmarais","year":"2013","journal-title":"Psychol Addict Behav"},{"key":"10.1016\/j.clinthera.2014.08.014_bib67","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1034\/j.1600-0447.107.s416.4.x","article-title":"The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment","volume":"107","author":"Haro","year":"2003","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.clinthera.2014.08.014_bib68","first-page":"299","article-title":"Schizophrenia, obesity and pharmacotherapy-associated weight gain","volume":"159","author":"Carpiniello","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2014.08.014_bib69","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814005529?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814005529?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:49:17Z","timestamp":1758962957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291814005529"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":69,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0149291814005529"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.08.014","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Prospective Flexible-Dose Study of Paliperidone Palmitate in Nonacute But Symptomatic Patients With Schizophrenia Previously Unsuccessfully Treated With Oral Antipsychotic Agents","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.08.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}